Production (Stage)
Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -65.52% | -18.59% | 7.05% | 118.41% | 1,413.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.52% | -18.59% | 7.05% | 118.41% | 1,413.24% |
| Cost of Revenue | -32.18% | -2.34% | 309.97% | 310.81% | 478.95% |
| Gross Profit | -66.25% | -19.82% | -9.17% | 109.44% | 1,469.34% |
| SG&A Expenses | -17.95% | -24.88% | 49.14% | 47.24% | 61.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.84% | -23.32% | 61.66% | 53.94% | 67.47% |
| Operating Income | -105.88% | 48.62% | -411.50% | -7.99% | 360.78% |
| Income Before Tax | -109.08% | 39.60% | -207.18% | -2.00% | 312.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.08% | 25.99% | -207.18% | -2.00% | 312.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.08% | 25.99% | -207.18% | -2.00% | 312.11% |
| EBIT | -105.88% | 48.62% | -411.50% | -7.99% | 360.78% |
| EBITDA | -105.41% | -- | -- | -- | -- |
| EPS Basic | -108.89% | 27.70% | -198.43% | 1.17% | 308.29% |
| Normalized Basic EPS | -108.89% | 43.61% | -200.23% | 1.17% | 309.53% |
| EPS Diluted | -110.29% | 18.90% | -199.15% | 3.14% | 278.26% |
| Normalized Diluted EPS | -110.24% | 43.61% | -200.23% | 1.17% | 282.00% |
| Average Basic Shares Outstanding | 1.97% | 2.34% | 2.91% | 3.17% | 1.83% |
| Average Diluted Shares Outstanding | -11.43% | 2.34% | 2.91% | 3.17% | 17.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |